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inherited retinal dystrophy associated with mutations in
CEP290. The deep intronic c.2991+1655A>G mutation in
CEP290 is the most common mutation in LCA10 individuals
and represents an ideal target for oligonucleotide therapeutics.
Here, a panel of antisense oligonucleotides was designed to
correct the splicing defect associated with the mutation and
screened for efﬁcacy and safety. This identiﬁed QR-110 as
the best-performing molecule. QR-110 restored wild-type
CEP290 mRNA and protein expression levels in CEP290
c.2991+1655A>G homozygous and compound heterozygous
LCA10 primary ﬁbroblasts. Furthermore, in homozygous
three-dimensional iPSC-derived retinal organoids, QR-110
showed a dose-dependent restoration of mRNA and protein
function, as measured by percentage and length of photore-
ceptor cilia, without off-target effects. Localization studies in
wild-type mice and rabbits showed that QR-110 readily reached
all retinal layers, with an estimated half-life of 58 days. It was
well tolerated following intravitreal injection in monkeys. In
conclusion, the pharmacodynamic, pharmacokinetic, and
safety properties make QR-110 a promising candidate for treat-
ing LCA10, and clinical development is currently ongoing.
INTRODUCTION
Currently, there is an urgent unmet need for treatment of Leber
congenital amaurosis type 10 (LCA10), an autosomal recessive in-
herited congenital blindness. LCA10 is caused by biallelic mutations
in centrosomal protein of 290 kDa (CEP290) and is the most common
form of LCA.1 An intronic mutation c.2991+1655A>G (also known
as p.Cys998*) is the most frequently occurring CEP290 mutation,
particularly in Europe and the USA, with between 60% and 90% of
LCA10 individuals having at least one c.2991+1655A>G allele.1–5
Unlike other CEP290 pathogenic mutations, which result in a more
severe syndromic presentation, major extra-ocular complications
are not reported for patients homozygous or compound heterozygous
for the CEP290 c.2991+1655A>G mutation.1–3,6730 Molecular Therapy: Nucleic Acids Vol. 12 September 2018 ª 2018
This is an open access article under the CC BY license (http://creatiStudies of patient-derived RNA with the c.2991+1655A>G mutation
revealed that a hypomorphic cryptic splice site in intron 26 is intro-
duced by the presence of the mutation.1,7–9 Consequently, two
CEP290 transcripts are produced: a mutant transcript containing an
extra cryptic exon (exon X) of 128 nucleotides that introduces a
premature stop codon (p.Cys998*) and a wild-type full-length tran-
script.1 The hypomorphic nature of the c.2991+1655A>G allele re-
sults in signiﬁcantly lower levels of wild-type CEP290 protein.
CEP290 is essential for the formation and stability of primary
cilia.10–13 The photoreceptor outer segment is a specialized primary
cilium that is essential for light detection and photoreceptor sur-
vival.14,15 The outer segment is continually renewed with proteins
and lipids synthesized in the inner segment, and is highly reliant on
the transport of proteins to the outer segment. Therefore, photorecep-
tors are particularly vulnerable to disruptions of cilia function.14,16
This might explain why reduced levels of CEP290 lead to retinal
dystrophy.17–19
Oligonucleotide-mediated pre-mRNA splice modulation is an estab-
lished mechanism that has been used to restore CEP290 mRNA and
protein function in LCA10 models. Using antisense oligonucleotides
to redirect normal splicing of CEP290 was ﬁrst demonstrated in
patient-derived ﬁbroblasts and immortalized lymphoblast cells.7,8
In a later study, induced pluripotent stem cells (iPSCs) derived
from ﬁbroblasts from a patient homozygous for the CEP290
c.2991+1655A>G mutation were used to produce retinal pigment
epithelium (RPE) and three-dimensional (3D) retinal organoids,The Author(s).
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgwhich contain a laminated retinal structure with an outer nuclear
layer (ONL) of photoreceptor-like cells, to study LCA10 pathogen-
esis.9 Interestingly, although all cell types showed reduced levels of
full-length CEP290 mRNA and defects in ciliogenesis, the 3D retinal
organoids showed the highest levels of aberrant splicing, with greater
defects in cilia formation.9 This increase in exon X incorporation
correlated with the differentiation of photoreceptors and the inclu-
sion of photoreceptor-speciﬁc exons in other mRNAs, suggesting a
potential basis for the retinal speciﬁcity of disease associated with
c.2991+1655A>G because of reduced levels of CEP290 in the retina
compared with other tissues.9 Furthermore, treatment of patient-
derived retinal organoids with an exon X-blocking morpholino-oligo-
nucleotide led to reduced levels of mutant transcript and increased
the level of wild-type CEP290 mRNA, with a consequent increase
in CEP290 protein expression. There was also a functional improve-
ment in the number and length of photoreceptor cilia and rescue of
cilia-associated protein localization, suggesting that this approach
could be a viable treatment option for LCA10.9
In this study, we describe the development of QR-110, a clinical drug
candidate oligonucleotide with potential to restore visual function, or
slow vision loss, in patients with LCA10. QR-110 is a single-stranded,
fully phosphorothioated, and 20 O-methyl-modiﬁed RNA oligonucle-
otide designed to correct the splicing defect resulting from the
CEP290 c.2991+1655A>G mutation. QR-110 represents a fully
optimized oligonucleotide that, as we show here, in both homozygous
and compound heterozygous ﬁbroblasts and homozygous retinal or-
ganoids carrying the CEP290 c.2991+1655A>G mutation, has the
capacity to signiﬁcantly restore wild-type CEP290 mRNA and
CEP290 protein, and is associated with increased ciliogenesis.
Moreover, QR-110 is effective when used gymnotically on retinal
organoids, has good accessibility to the retina following intravitreal
(IVT) injection, and demonstrates good tolerability following IVT
injection. This makes QR-110 an excellent candidate for clinical
development.
RESULTS
Identification of Lead Oligonucleotide Targeting the CEP290
c.2991+1655A>G Mutation
A total of 29 oligonucleotides were designed using an oligo-walk
approach around the exon X sequence and were screened in homo-
zygous CEP290 c.2991+1665A>G LCA10 patient ﬁbroblasts for
reduced aberrant splicing and increased production of wild-type
CEP290 mRNA. Oligonucleotides were also screened by in silico
methods for lack of secondary structures or immune-stimulatory
motifs, and suitability for large-scale manufacturing. This approach
identiﬁed three best-performing oligonucleotides (leads 1–3) (Fig-
ure S1), which were further screened for pro-inﬂammatory potential
using in vitro peripheral blood mononuclear cell (PBMC) assay
(panel of ﬁve independent donors). None of the oligonucleotides
had a signiﬁcant effect on PBMC viability (Figure S2), but PBMC
challenge by lead 1 resulted in signiﬁcant induction of cytokine
expression (Figure S3). A mild cytokine response was observed for
lead 3 and none for lead 2; therefore, leads 2 and 3 were chosenfor in vivo tolerability assessment. The rabbit is a highly sensitive
species for ocular therapeutics dosed via IVT injection and often
develops severe ocular inﬂammation.20,21 This exaggerated response
is advantageous for the initial immune-inﬂammatory screening of
oligonucleotides. In rabbits, lead 2 was better tolerated than lead 3
(Figure S4A). Finally, tolerability of lead 2 was determined in cyno-
molgus monkey, the preferred nonclinical toxicological species for
ocular therapeutics. Monkeys were given an IVT injection of 60 or
100 mg of oligonucleotide per eye (equivalent to 6 and 10 mM,
respectively) and studied for 28 days. This single dose of lead 2
was well tolerated without any signiﬁcant ﬁndings (Figure S4B). In
a later monkey study this oligo was studied, in a single dose setting,
up to 900 mg of oligonucleotide per eye (equivalent to 93 mM), and
was well tolerated at least up to 28 days (Figure S4C). Based on this
screening, the lead 2 (QR-110) oligonucleotide emerged as the best-
performing molecule and was used for further characterization.
QR-110Oligonucleotide Treatment RestoresCEP290mRNAand
Protein in Patient Fibroblasts
Fibroblasts from two homozygous CEP290 c.2991+1665A>G LCA10
patients and from two compound heterozygous LCA10 patients
with CEP290 c.2991+1665A>G in trans with c.4723A>T
(p.Lys1575*) (compound het 1) and c.5668G>T (p.Gly1890*)
(compound het 2) were characterized. The levels of CEP290
transcripts containing exons 26-27 and X-27 (Figure S5A) were
quantiﬁed by digital droplet PCR (ddPCR). LCA10 cells expressed
signiﬁcantly reduced levels of wild-type CEP290 exon 26-27
mRNA compared with control cells (Figures 1A and S5). Transcripts
containing exon X were detectable only in the LCA10 cells, and not
in the control cells. As expected, the levels of exon X-27 were highest
in the homozygous c.2991+1665A>G cells, with lower levels in the
compound heterozygous cells (Figure 1B). In the compound
heterozygous cells, the levels of mutant c.4723A>T and c.5668G>T
CEP290 transcripts were measured by ddPCR and Sanger
sequencing, respectively (Figure S5). The levels of c.4723A>T tran-
script were substantially lower than the 26-27 transcript in com-
pound het 1, and the levels of c.5668G>T were reduced in cDNA
compared with genomic DNA, probably as a result of nonsense-
mediated decay due to the presence of premature stop codons in
the trans alleles (Figure S5).
QR-110 treatment increased CEP290 wild-type (26-27) levels in both
homozygous and compound heterozygous LCA cells in a dose-depen-
dent manner (Figure 1A), with simultaneous reduction in exon
X-containing transcripts (X-27) (Figure 1B). The increase in
CEP290 transcript levels was translated into a detectable increase in
full-length CEP290 protein levels measured by immunoblotting (Fig-
ures 1C and 1D). A scrambled oligonucleotide control of the same
length and chemistry had no effect on any of these parameters within
the same experiments (Figures 1A–1D). Importantly, QR-110 treat-
ment resulted in an increase in CEP290 mRNA and protein levels
in homozygous LCA10 ﬁbroblasts similar to the control cell line
levels, or approximately half that of control cell line levels in com-
pound heterozygous LCA10 ﬁbroblasts (Figures 1A and 1D). TheMolecular Therapy: Nucleic Acids Vol. 12 September 2018 731
Figure 1. QR-110 Increases Wild-Type CEP290
mRNA and Protein Levels in c.2991+1655A>G
Homozygous and Compound Heterozygous LCA
Primary Fibroblasts
(A–D) Quantification of (A) wild-type transcript (exon
26-27), (B) c.2991+1655A>G mutant transcript (exon
X-27), and (C and D) protein in control and c.2991+
1655A>G homozygous and compound heterozygous
primary fibroblasts following treatment with QR-110.
Control and LCA cells were treated with different con-
centrations of QR-110 using PEI-mediated transfection
and harvested after 24 (RNA) or 72 hr (proteins). Mock:
transfection reagent only; scrambled: different sequence
control oligonucleotide with same length and chemistry.
mRNA levels were determined by one-step isoform-spe-
cific RT-ddPCR. (C) Representative CEP290 immunoblot
images from different LCA cell lines. (D) Protein signal was
quantified (n = 3 biological replicates per cell line) by
densitometry analysis, normalized by protein load (LC),
measured by UV illumination of Stain-free gel, and ex-
pressed relative to control cell levels. Data are represented
asmean±SEM. *p<0.05; **p<0.01 (Student t test versus
mock-treated LCA cells). Compound heterozygous cells
had the following genotypes: compound heterozygous 1
(c.2991+1655A>G/c.4723A>T) and compound hetero-
zygous 2 (c.2991+1655A>G/c.5668G>T).
Molecular Therapy: Nucleic Acidsreduced impact of QR-110 on the heterozygous cells was expected
because these cells contain only one c.2991+1655A>G allele that
can be targeted by QR-110.
QR-110 Photoreceptor Accessibility and Stability In Vivo
To test the biodistribution of QR-110 in the eye, biotin-labeled
QR-110 and 6-carboxyﬂuorescein (6-FAM)-labeled QR-110 were
used to investigate the ability of QR-110 to reach the photoreceptor
ONL, the intended target site for splice correction, after IVT injec-
tion in both Dutch-belted rabbits and C57BL/6 mice. The presence
of QR-110 was noted in all retinal layers, including the RPE,
following IVT injection in both rabbits and mice (Figure 2). The
signal was more prominent in the ganglion cell layer and inner nu-
clear layer, which are closer to the site of injection, and at the outer
limiting membrane. This pattern of distribution is consistent with
other oligonucleotides administered through the IVT route.22,23 In
rabbit retina, diffuse perinuclear distribution was seen immediately
following the IVT injection of biotin-labeled QR-110 and with
time developed to an abundant punctate signal (Figure 2A). This in-
dicates a rapid uptake of QR-110 by retinal cells followed by long
retention in the retina. This was further supported by a complemen-
tary study that quantitatively analyzed QR-110 levels in rabbit retina
by hybridization ELISA at different time points following IVT injec-
tion (Figure 2B). Linear regression analysis of QR-110 levels in the
rabbit retina estimated the retinal half-life at 58 days (R2 = 0.87).
6-FAM-labeled QR-110 showed similar localization in the mouse
retina and was also detected at 60 days post-IVT injection (Fig-
ure 2C). No retinal staining was observed when PBS or either of732 Molecular Therapy: Nucleic Acids Vol. 12 September 2018the conjugated labels only (without oligonucleotide) was injected
at similar molar concentrations (Figures 2A and 2C). Similarly,
6-FAM-labeled QR-110 readily entered the surrogate ONL of con-
trol iPSC-retinal organoids and was detected in both the nucleus
and the cytoplasm (Figure 2D). These data suggest that QR-110
can access iPSC-derived photoreceptors in 3D organoids following
gymnotic treatment, without the need for transfection reagent,
which is consistent with their ability to access retinal cells in animals
following IVT injection.
QR-110 Treatment Reduces Aberrant Splicing, Increases
Wild-Type CEP290 in Homozygous Retinal Organoids, and
Shows No Off-Target Pharmacology
There is no suitable animal model for the c.2991+1665A>G-mediated
CEP290 splicing defect to study the efﬁcacy of QR-110 in retina.
Indeed, previous attempts to generate a humanized CEP290 knockin
mouse with the speciﬁc c.2991+1655A>G intronic mutation yielded a
mouse with no ocular phenotype and limited recognition of the
human intronic mutation by the mouse spliceosome.24,25 Patient
iPSC-derived 3D retinal organoids have been used as a relevant test
system to show the efﬁcacy of targeting the c.2991+1655A>G
intronic mutation.9 In addition, retinal organoids allow testing of
drug candidates in differentiated human photoreceptors, which has
a number of unique advantages for studying pathogenic mutations
leading to defective splicing, because these mutations may not be
recognized by the splicing machinery of other species.24 Therefore,
a 3D retinal organoid model was used for further characterization
of the efﬁcacy of QR-110.
Figure 2. QR-110 Has Good Photoreceptor
Accessibility and Stability following Intravitreal
Injection
(A) Representative confocal images from Dutch-Belted
rabbit retina, at 5 min and 13 days after single IVT of
biotin-labeled QR-110 (600 mg). Control animals received
PBS and no oligonucleotide. (B) Quantification of QR-110
in Dutch-Belted rabbit retina using hybridization ELISA
based on probes complementary to QR-110. Data are
represented as mean ± SEM and as microgram of
QR-110 per gram of retina. Rabbits were bilaterally dosed
(minimum three animals per time point) with a single IVT
injection of 100 mg of QR-110 (equivalent to 14.17 mM)
and were sacrificed at 0.5, 4, 13, 34, 51, and 101 days.
The shape of the QR-110 retinal concentration curve in-
dicates fast uptake and slow elimination, and linear
regression analysis (red line) of QR-110 concentration in
the elimination phase calculated a retinal half-life of
58 days (R2 = 0.87). (C) Images of C57BL/6 mouse retina
at 14 and 60 days after single IVT injection of 6-FAM-
labeled QR-110 (100 mg). Control animals received
unconjugated 6-FAM only and no oligonucleotide. (D) Live
confocal imaging of retinal organoids, derived from con-
trol iPSCs, 48 hr after treatment with 6-FAM-labeled
10 mM QR-110 oligonucleotide (green) or untreated
control, counterstained with Hoechst nuclear dye (blue).
Larger images show 6-FAM-QR-110 penetrance through
all cell layers. Insets show diffuse fluorescence in the
cytoplasm and nucleus, as well as some punctate peri-
nuclear staining. Scale bars, 20 mm (A and C); 100 mm
(D,main image); 10 mm (D, inset). GCL, ganglion cell layer;
INL, inner nuclear layer; OLM, outer limiting membrane;
ONL, outer nuclear layer.
www.moleculartherapy.orgHomozygous CEP290 c.2991+1655A>G iPSCs were produced from
patient ﬁbroblasts and characterized, as previously described,9 and
then further differentiated into 3D retinal organoids. Recoverin and
cone arrestin immunoreactive cells in the ONL of the retinal organo-
ids and PCR analyses of photoreceptor differentiation markers (CRX,
NRL, and NR2E3) conﬁrmed the presence of photoreceptor-like cells
and no effect on the expression of these photoreceptor markers
following oligonucleotide treatment (Figures 3A–3C). Retinal orga-
noids were gymnotically treated with QR-110. The concentrations
of QR-110 were higher than those used in transfected ﬁbroblasts
and similar to those used previously for morpholino with Endoporter
treatment of retinal organoids.9
RT-PCR analysis of QR-110-treated retinal organoids showed
signiﬁcantly increased levels of the correctly spliced, wild-type
CEP290 (exon 26-27) transcript and a reduction in the transcript
containing the cryptic exon (26-X-27) (Figures 3D and 3E). Wild-
type transcript levels were increased in a dose-dependent manner,
reaching more than 90% of the total transcript after treating with
10 mM QR-110. All concentrations of QR-110 led to an increase
in the proportion of the wild-type transcript. This was furtherconﬁrmed by quantitative ddPCR analysis. Increases relative to un-
treated retinal organoids ranged from 20% at 0.3 mM QR-110 to
approximately 140% at 1 or 3 mM QR-110, further increasing to
500% at 10 mM QR-110 (Figure 3F). QR-110 treatment also evoked
notable and statistically signiﬁcant reductions in the cryptic exon
transcript (26-X-27) CEP290; however, these reductions were not
as dose related as the changes in wild-type transcript, with the
maximum effect already observed at 3 mM QR-110 (Figure 3G).
Similar results were observed in retinal organoids gymnotically
treated with lead 3 oligonucleotide, demonstrating that the uptake
and distribution are independent of sequence and are likely driven
by the phosphorothioate chemistry of the oligonucleotide
(Figure S6).
The effect of QR-110 on potential mRNA targets other than
CEP290 in retinal organoids was also investigated. Bioinformatic
analyses identiﬁed no targets at the mRNA level with full comple-
mentarity to the QR-110 sequence; however, some potential off-
target locations deep in intronic regions far from exon-intron
junctions were identiﬁed in pre-mRNAs. FANCD2 and C8orf37
were prioritized because they are the top BLAST hits to mRNAMolecular Therapy: Nucleic Acids Vol. 12 September 2018 733
Figure 3. QR-110 Treatment Specifically Increases
Wild-Type CEP290 mRNA in Homozygous LCA
Retinal Organoids
Retinal organoids treated with culture medium only
(untreated) or culture medium containing different con-
centrations of QR-110 twice per week, starting from day
96 of maturation, for 4 weeks before assessment at day
124. (A) Recoverin (red) and cone-arrestin (green) staining
of retinal organoids used in this study. Scale bar, 10 mm.
(B and C) ddPCR quantification (B) and RT-PCR analysis
(C) of photoreceptor differentiation marker genes
in representative untreated and QR-110-treated homo-
zygous CEP290 c.2991+1655A>G LCA retinal organo-
ids, at the end of treatment, confirming organoid matu-
ration. FB, fibroblasts; RO, retinal organoids. (D)
Representative RT-PCR results of CEP290 exons 26-27
and 26-X-27. (E) Quantification of bands in homozygous
c.2991+1655A>G LCA10 retinal organoids (n = 5–6
retinal organoids per condition) showed a significant in-
crease in wild-type CEP290 in a dose-response manner,
which was further confirmed by isoform-specific
RT-ddPCR quantification of CEP290 (F) wild-type (exon
26-27) and (G) mutant transcript (exon 26-X-27) levels
(n = 2–3 per condition). A similar dose response to
QR-110 treatment was not observed for potential QR-110
off-targets, (H) FANCD2 and (I) C8orf37, identified by
bioinformatics analysis. Gene-specific ddPCR quantifi-
cation of FANCD2 and C8orf37 was investigated in
homozygous LCA retinal organoids (n = 2–3 per condi-
tion). Statistically insignificant difference (versus un-
treated) was found for these targets, and no trend of
upregulation or downregulation was noticed. Data are
represented as mean ± SEM. Student t test versus un-
treated, **p < 0.01; ***p < 0.001.
Molecular Therapy: Nucleic Acidswith 16/17 base homology to QR-110; furthermore, C8orf37 was
chosen due to its functional relevance in the retina (Figures 3H
and 3I).26 Four additional potential pre-mRNA off-target hits
(AFF4, ATXN2, CTNNA1, and PTGER3) with a 100% match to
QR-110 in their intronic region were selected based on: (1)
QR-110 binding distance to the nearest exon, (2) expression level734 Molecular Therapy: Nucleic Acids Vol. 12 September 2018in retina, and (3) the number of PubMed
results for terms “gene name” and “eye.” The
insulin receptor, INRS, which has a 16/17
match to QR-110 in the sense strand of the
gene sequence, but does not target the
mRNA, was also investigated (Figure S7).
Analysis of these off-target effects showed
that QR-110 had little or no effect on these
targets, highlighting the requirement for full
complementarity and/or the presence of
important regulatory elements at the site of
oligonucleotide binding for on- or off-target
activity (Figures 3H, 3I, and S7). It is note-
worthy that in these experiments, which illus-
trated no effect of QR-110 on these potentialoff-target sequences, QR-110 was effective in correcting the
splicing defect in the CEP290 c.2991+1655A>G mRNA (Figures
3D–3G).
We also performed RNA-sequencing (RNA-seq) to complement
this sequence homology-based study with an unbiased approach
Figure 4. QR-110 Treatment Rescues Ciliation and
Increases Cilia Length in c.2991+1655A>G
Homozygous LCA Retinal Organoids
Retinal organoids were treated with culture medium only
(untreated) or different concentrations of QR-110 from
day 96 before assessment at day 124. Representative
images of cilia (Arl13, red; pericentrin, green; nuclei, blue)
in (A) untreated wild-type control and LCA homozygous
c.2991+1655A>G retinal organoids and (B) QR-110-
treated LCA homozygous c.2991+1655A>G retinal
organoids. Insets show a higher magnification of a cilium.
Quantification of cilia (C) incidence and (D) length in retinal
organoids treated with 0.3, 1, 3, or 10 mM QR-110. Data
are represented as mean ± SEM. Student’s t test, versus
untreated retinal organoids, *p < 0.05; **p < 0.01. At least
900 basal bodies were scored in each retinal organoid;
n = 3 for control and LCA retinal organoids per condition.
(A and B) Scale bars, 10 mm (main image); 1 mm (inset).
www.moleculartherapy.organd identify other potential hybridization-dependent off-targets.
Transcriptome analysis was performed to assess the hybridiza-
tion-dependent off-target effects using two untreated and two
1 mM QR-110-treated LCA10 retinal organoids. This dose was
selected because it was effective at suppressing exon X (Figure 3),
suggesting effective hybridization and blocking activity, but it did
not signiﬁcantly increase CEP290 26-27 mRNA (Figure 3F). There-
fore, increased levels of CEP290 mRNA, such as those observed at
higher concentrations of QR-110, which could have wider, down-
stream “on-target” effects, would not confound the identiﬁcation
of genuine “off-target” effects. Using a 2-fold change as a cutoff,
44 differentially expressed genes were identiﬁed, but none has
complementarity to QR-110 (Table S8). This number of differential
genes in QR-110-treated organoids is similar to transcriptome
changes observed for other antisense oligonucleotides and small-
molecule drugs.27 Importantly, none of the seven downregulated
genes have been associated with retinal dysfunction. In combina-
tion with the selected gene analyses, these data suggest QR-110
does not have any major off-target activity.Molecular TherapQR-110 Treatment Restores Ciliogenesis in
CEP290 Homozygous Retinal Organoids
The reduced levels of CEP290 in LCA10 retinal
organoids are associated with defects in photo-
receptor ciliation, illustrated by underdeveloped
mother centrioles, incompletely formed ciliary
vesicles, and membrane-less cilia.9,19 The effect
of QR-110 on ciliogenesis was investigated in
CEP290 c.2991+1655A>G homozygous retinal
organoids. Speciﬁcally, the number of ciliated
cells and the average length of the cilia were
assessed (Figure 4). Cilia incidence was
measured in the surrogate ONL of retinal orga-
noids by scoring the number of pericentrin-
positive basal bodies that were positive for
Arl13b (a cilia axoneme marker), and cilialength was measured by quantifying the length of each Arl13b
immunopositive axoneme. At low concentrations of QR-110, such
as 0.3 and 1 mM, no signiﬁcant change in either the percentage of
ciliated cells or cilia length was observed. In contrast, treatment
with 3 mMQR-110 led to a signiﬁcant increase (12%) in the percent-
age of ciliated cells, but the average cilia length remained unchanged;
however, 10 mM QR-110 treatment signiﬁcantly increased both the
incidence (50% increase; Figure 4C) and average length of cilia
(27% increase; Figure 4D). At this dose, 74% of the cells were ciliated
with an average length over 1 mm, which is a similar cilia incidence
and length to the photoreceptor ONL in retinal organoids prepared
from healthy control iPSCs (Figures 4C and 4D).
DISCUSSION
The recent success of gene therapy approaches for inherited retinal
dystrophies highlights the potential to achieve improved outcomes
in these patient populations by targeting the speciﬁc underlying
genetic defect.28,29 Large proteins such as CEP290, however, are not
deliverable through current AAV gene therapy vectors30 and requirey: Nucleic Acids Vol. 12 September 2018 735
Molecular Therapy: Nucleic Acidssmaller fragments to be used.31 Although intronic mutations, such as
in CEP290 c.2991+1655A>G, are an attractive target for gene-editing
strategies,32,33 potential off-target editing, which is irreversible, is a
major concern.34 Furthermore, gene replacement or gene editing
would require high levels of transduction to rescue as many cells as
possible. Hence, for such indications, oligonucleotide therapeutics
provides an attractive alternative. Previous studies have provided
in vitro proof of concept for the potential of using oligonucleotide-
based splice correction therapy for CEP290 c.2991+1655A>G,7–9
and the ability of oligonucleotides to reach photoreceptor nuclei
in vivo following IVT injection.22,23,35 In addition to potency and
delivery, however, a clinical molecule should have a pharmacokinetic
proﬁle that supports a feasible dosing regimen, taking into account
the ocular administration route, and a safety proﬁle indicative of a
positive beneﬁt to risk balance. Therefore, in this study, we have
assessed oligonucleotides not only for efﬁcacy, but also for off-target
effects, tolerability, and clinical feasibility.
QR-110 oligonucleotide treatment demonstrated a profound concen-
tration-dependent efﬁcacy in both homozygous and compound
heterozygous LCA10 ﬁbroblast and LCA10 homozygous retinal orga-
noid models, by mediating splice correction of the exon X-containing
CEP290 mRNA and yielding increased levels of wild-type CEP290
mRNA. Unlike in ﬁbroblasts, where transfection reagents are
required, QR-110 readily entered the surrogate ONL in 3D retinal
organoids. This cellular entry of oligonucleotides is proposed to be
a feature of oligonucleotides bearing phosphorothioate linkages.
The entry of QR-110 into the ONL of the retina was demonstrated
in mice using ﬂuorescence labeling and further demonstrated in the
rabbit retina with biotin labeling and ELISA. QR-110 is able to pene-
trate all cellular layers within the retina including the ganglion cell
layer, the inner nuclear layer, the ONL, and also the RPE, with the
initial exposure in close proximity to the vitreous. Greater exposure
of QR-110 to the ONL could potentially be driven by sub-retinal
injection or supra-choroidal delivery; however, sub-retinal delivery
is a more complicated procedure than IVT injection and unlikely to
be used as a regular route of delivery for a reversible therapeutic
approach, such as that proposed here. As in the case for other IVT
injections and products, so long as there are no adverse consequences
of high local concentrations and the target tissue is exposed to a ther-
apeutic level, IVT injections remain a safe and effective route of
administration.
QR-110 was shown to be present in the ONL of mouse retina 60 days
post-IVT injection, and studies in rabbit suggest an estimated retinal
half-life of approximately 58 days, which is consistent with other ob-
servations of oligonucleotides with similar chemistry, administered to
large eyes by IVT injection.36 Rabbits are known to be very sensitive to
IVT injections,21 and the IVT injection of 100 mg of QR-110 was asso-
ciated with a moderate inﬂammatory reaction. This inﬂammatory
response could have adversely affected the observed half-life, whereas
QR-110 was better tolerated in non-human primates. Initial safety
assessment of QR-110 was performed in cynomolgus monkey. In a
single dose setting of 900 mg per eye, QR-110 was well tolerated for736 Molecular Therapy: Nucleic Acids Vol. 12 September 2018up to 28 days, and no adverse ﬁndings related to QR-110 were
observed (Figure S4). Therefore, the long half-life of QR-110 should
permit infrequent dosing in the range of 3–6 months, which is essen-
tial in the clinic given the invasiveness of the IVT injection procedure,
but the optimal dosing regimen will need to be determined in clinical
studies.
The CEP290 c.2991+1655A>G homozygous patients comprise only
10%–20% of the LCA10 population, whereas the mutation is reported
in compound heterozygosity in >75% of LCA10 patients.2,37
The clinical presentation of LCA10 is variable and shows an apparent
dissociation of structure and function in many patients.4,38 Optical
coherence tomography reveals that almost all patients have
central photoreceptor preservation, but vision can range from no light
perception to 20/50.4,38 The reasons for this are currently unclear, and
larger detailed studies are needed to better understand any correlation
between genotype and phenotype. Nevertheless, the presence of
central photoreceptors in most LCA10 patients suggests that their
function and survival could be improved by enhanced CEP290
function. Furthermore, LCA10 is a recessive disease with asymptom-
atic carriers, such that increasing CEP290 levels up to 50% of
control CEP290 protein should be sufﬁcient to mediate some
functional rescue. Importantly, QR-110 treatment of compound
heterozygous ﬁbroblasts increased full-length CEP290 protein to
40%–50% of control levels. Homozygous CEP290 c.2991+1655A>G
retinal organoids have higher levels of aberrant splicing than
ﬁbroblasts;9 nonetheless, the ability of QR-110 to increase the level
of wild-type CEP290 transcript to over 60% of control levels in
homozygous retinal organoids with ciliation and cilia length near
wild-type control levels suggests that QR-110 could be able to restore
sufﬁcient wild-type transcript, even in compound heterozygous
photoreceptors.
The use and availability of human patient-derived stem cells that can
be differentiated into many different cell types has revolutionized
pharmacological approaches to study interventional approaches to
inherited disease.13 In retinal dystrophy, 3D retinal organoids allow
the direct study of a human therapeutic, without reference to spe-
cies-speciﬁc molecules, which is particularly important for oligonu-
cleotide therapeutics. Furthermore, the study can be focused on the
causative mutation in the relevant genomic context. It has previously
been observed that a human knockin transgenic mouse containing
the CEP290 c.2991+1655A>G allele is not as useful as hoped for
studying aberrant splicing, because the human gene is processed
differently by the mouse photoreceptors and has different splicing
enhancer recognition,24,25 a situation that might occur when trying
to model other deep-intronic mutations in this way. Furthermore,
human retinal organoids allow retina-speciﬁc theoretical off-target
effects to be studied, and ﬁnally they allow an estimation of the neces-
sary effective vitreal concentration of therapeutic, which can be used
to estimate clinical doses in human clinical trials.
Although oligonucleotides are an emerging class of therapeutic
agents, retinal diseases such as CMV retinitis and age-related
www.moleculartherapy.orgmacular degeneration have already been demonstrated to be
amenable to IVT administration of oligonucleotide therapies.39–41
Vitravene and Macugen, albeit working by different mechanisms
of action, are proven oligonucleotide drug therapies for these
ophthalmic indications.42,43 Two antisense oligonucleotides that
target pre-mRNA splicing modulation have recently received mar-
keting authorization: Spinraza for spinal muscular atrophy and
Exondys51 for Duchenne’s muscular dystrophy.44,45 Oligonucleo-
tide therapeutics targeted at editing pre-mRNA are very selective,
with few, if any, off-target effects. They have predicable delivery
to all cellular layers of the retina and have a long retinal half-life,
allowing for infrequent IVT dosing. Therefore, such therapeutics
could be applicable to a wide range of monogenic inherited retinal
dystrophies. Importantly, the process of modulating pre-mRNA
splicing ensures that the impact of the RNA therapeutic is fully
reversible, and that the maximum treatment effect can only be to
restore normal levels of target mRNA. This is potentially important
in LCA10, because it has been noted previously that overexpression
of CEP290 is associated with cellular toxicity.46 Therapeutic oligo-
nucleotides, such as QR-110, do not pose such a risk, and their
excellent safety proﬁles and efﬁcacy encourage translation to the
clinic.
MATERIALS AND METHODS
Animal Care
In-life phase of the rabbit (and monkey) studies were carried out by
external contract research organizations (CROs) (Covance Labora-
tories, USA [rabbit] and Charles River Laboratories, Canada [mon-
key]) who obtained relevant approvals, and the studies conform to
all relevant regulatory standards. The mice used in this study were
all female C57BL/6J mice 6–7 weeks of age at the time of purchase
from a commercial supplier (Charles River). All procedures on
mice were conducted according to the Home Ofﬁce (UK) regulations,
under the Animals (Scientiﬁc Procedures) Act of 1986, and with local
(UCL-Institute of Ophthamology, London, UK) ethics committee
approval. Animals were maintained at constant 12-hr light-dark cycle
with access to food and water ad libitum for at least 1 week prior to
initiating IVT injections, which were performed as described previ-
ously.47 Rabbits used in this study were all males, aged 3–4 months,
housed in individual, suspended cages with appropriate enrichment
devices. Animals were acclimatized for at least 7 days prior to IVT
injection.
Cell Culture and QR-110 Transfection
Fibroblasts (see Table S1) were generated from skin biopsies as
previously described.48 Cell lines were cultured in DMEM-high-
glucose AQmedia (Sigma-Aldrich) supplemented with 20% fetal
bovine serum (FBS; Biowest, France) and 1% sodium pyruvate
(Sigma-Aldrich). Fibroblasts were transfected with oligonucleotides
(see Table S2) using polyethyleneimine (PEI) Max transfection re-
agent (Polysciences, Germany) with an oligo-to-PEI ratio of 1:4 and
incubated for 24 hr (RNA analysis) or 3 days (protein analysis) at
37C. Alternatively, cells were mock treated with transfection reagent
only, without oligonucleotide.3D Retinal Organoids and QR-110 Treatment
iPSCs were generated from c.2991+1655A>G homozygous ﬁbro-
blasts using three integration-free episomal plasmids from Addg-
ene: pCXLE-hOCT3/4-shp53-F, pCXLE-hUL, and pCXLE-hSK.
Reprogramming was performed as described previously.9,49,50 In
brief, 1  106 cells were electroporated with 1 mg of each plasmid
using the Amaxa Nucleofector I device and cultured on 0.1%
gelatin-coated dishes in DMEM (Life Technologies) supplemented
with 10% FBS (Lonza), 1 mM non-essential amino acids (NEAA)
(Life Technologies), 1 mM GlutaMAX (Life Technologies),
0.5 mM sodium butyrate (Sigma-Aldrich), and 1% penicillin and
streptomycin (Life Technologies). After 7 days, the cells were
replated at 2  105 cells per well into six Geltrex (Life Technolo-
gies)-coated wells. The next day, the media were changed to
Essential-8 (E8) media (Life Technologies) supplemented with
0.5 mM sodium butyrate for a further 6 days, after which the cells
were cultured in E8 media until iPSC colonies appeared (approxi-
mately 25 days). Clonal iPSC lines were mechanically isolated and
maintained in E8 media.
Directed differentiation of iPSCs into 3D retinal organoids was
based on the protocol by Nakano et al.50 Table S3 summarizes
the different media used for differentiation. iPSCs were dissociated
using TrypLE (Life Technologies) and plated at a density of
9,000 cells per well in V-shaped 96-well plates in E8 supplemented
with 10 mM Y-27632 (Millipore) (day 0). From days 2–14,
medium was exchanged every 2 days with embryoid body 1
(EB1) medium and from days 14–20 with EB2 medium every
3–4 days. At day 20, the embryoid bodies were transferred to
non-adherent 25-well plates, and EB2 medium was exchanged
for neural retinal differentiation (NR) medium every 3–4 days
for up to 17 weeks.
LCA homozygous retinal organoids were treated with 0.3, 1, 3, or
10 mM QR-110, diluted in NR medium supplemented with 0.5 mM
retinoic acid. A total of eight doses, twice per week, was given from
day 96 until day 124. The localization of the QR-110 was assayed
following the treatment of wild-type retinal organoids, at day 96,
with 10 mM 6-FAM-labeled QR-110 for 48 hr.
RT-PCR
RNA was extracted from the organoids using RNeasy Mini Kit
(QIAGEN), and cDNA synthesis was performed using Tetro cDNA
synthesis kit (Bioline). CEP290, retinal differentiation markers
(CRX, NRL, and NR2E3), and GAPDH were ampliﬁed by PCR using
GoTaq Green (Promega) with standard cycling conditions. Primers
used for RT-PCR are listed in Table S4. Densitometry analysis of
the bands was performed using ImageJ. Student’s t test (two-tailed,
equal variance) was used for statistical analysis.
Digital Droplet PCR
RNA was isolated from the ﬁbroblasts using the RNeasy Plus Mini kit
(QIAGEN). ddPCR was performed, except for the c.4723A>T assay,
using the One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad)Molecular Therapy: Nucleic Acids Vol. 12 September 2018 737
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Primers and probes used are listed in Table S4. Assays contained
900 nM forward and reverse primer each and 250-nM-labeled probe.
The CEP290 c.4723A>T (p.Lys1575X) assay was performed using
two-step ddPCR. First, cDNA was synthesized from 1 mg of RNA us-
ing Maxima Reverse Transcriptase and Random Hexamers (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instructions. Then
ddPCRs were prepared containing 1 QX200 ddPCR EvaGreen
Supermix (Bio-Rad), 900 nM forward and reverse primer each, and
50 ng of cDNA. The ddPCR programs are summarized in Table S5.
Each sample was analyzed in duplicate. Absolute quantiﬁcation was
performed in QuantaSoft software (Bio-Rad). The copy number
was divided by the amount of input RNA (in nanogram) and normal-
ized to geometric mean of GUSB and HPRT1 (and multiplied by
average GUSB and HPRT1 geometric mean of all samples, as a con-
stant). Student’s t test (two-tailed, equal variance) was used for statis-
tical analysis.
Western Blotting
Cell pellets were lysed in radioimmunoprecipitation assay (RIPA)
protein lysis buffer supplemented with protease inhibitor cocktail
(Roche) and further homogenized using a 29G needle. Protein
concentrations were determined using the Pierce BCA Protein
Assay Kit (Thermo Scientiﬁc). The protein samples (80 mg) were
loaded onto a Stain-free 4%–15% precast Mini-Protein TGX gel
(Bio-Rad), followed by transfer to polyvinylidene ﬂuoride
(PVDF) membranes (Millipore). After 1-hr incubation with
Odyssey Blocking Buffer (Li-Cor), the membranes were probed
overnight with polyclonal rabbit anti-human CEP290 antibody
(1:1,000; Novus Biologicals), followed by 1-hr incubation with
goat anti-rabbit IRDye 680RD (1:10,000; Li-Cor). The membranes
were scanned with the Odyssey CLx Imager (Li-Cor) using Image
Studio Lite software. The total protein load (visualized by 1-min
UV activation of the protein gel using the GelDoc XR+ system)
and the CEP290 protein signal were quantiﬁed with Image Studio
Lite software. The CEP290 signal was normalized to the total pro-
tein load. Student’s t test on log2-transformed data was used for
statistical analysis.
Cilia Assay and Immunofluorescence
Organoids were removed from culture media and ﬁxed in 4% parafor-
maldehyde at 4C for 30 min. Post-ﬁxation retinal organoids were
cryoprotected by incubation overnight in 30% sucrose in PBS and
then frozen and cyrosectioned. Cryosections were incubated in block-
ing buffer (3% BSA and 10% normal donkey serum in PBS) for 1 hr
at room temperature before incubation with primary antibodies
(Table S6) for 2 hr at room temperature. Species-speciﬁc anti-IgG
Alexa Fluor 488 or 594 secondary antibodies were used, and nuclei
were visualized using DAPI (2 mg/mL). Images were obtained using
a Carl Zeiss LSM700 laser-scanning confocal microscope, except for
the high-magniﬁcation images that were obtained using the Airyscan
mode on a Carl Zeiss LSM710 microscope. Images were exported
from Zen 2009 software and prepared using Adobe Photoshop and
Illustrator CS4. All measurements were performed in ImageJ and738 Molecular Therapy: Nucleic Acids Vol. 12 September 2018Adobe Photoshop. For cilia measurements, maximum intensity
projections of z stacks were used in the analysis. The incidence of or-
ganoid ciliation (%) was determined by counting the total number of
pericentrin immunopositive structures associated with Arl13b immu-
nopositive cilia. Cilia length was assessed bymeasuring Arl13-positive
cilia length using Adobe Photoshop. Student’s t test (two-tailed, equal
variance) was used for statistical analysis.
QR-110 Localization in Retina
Dutch-Belted rabbits were sacriﬁced 5 min or 13 days after IVT
injection of 600 mg of biotin-labeled QR-110. Rabbit eyes were
removed and ﬁxed in modiﬁed Davidson’s ﬁxative, transferred to
70% ethanol, and embedded in parafﬁn. Tissue sections were depar-
afﬁnized, and biotin-labeled QR-110 was visualized using streptavi-
din-Alexa 647. Images were acquired on an LSM800 confocal micro-
scope (Zeiss).
C57BL/6 mice were sacriﬁced 14 or 60 days after IVT injection of
100 mg of 6-FAM-labeled QR-110. Mice eyes were ﬁxed overnight
at 4C in 4% paraformaldehyde and transferred to 30% sucrose.
Posterior chambers were dissected and lenses removed before embed-
ding and freezing in OCT compound. 6-FAM-labeled QR-110 was
directly visualized in cryosections, and images were acquired on an
LSM700 confocal microscope (Zeiss).
Wild-type control retinal organoids, at day 96, were treated with
10 mM 6-FAM-QR-110 diluted in NR media or NR media alone
and were kept in the dark for the duration of the treatment. After
48-hr incubation, retinal organoids were washed twice with NR
media, stained with Hoechst for 20 min, washed with NR media,
and imaged live on the Zeiss LSM 510 inverted confocal microscope
with heated stage.
QR-110 Quantitation by ELISA
Rabbit retinas were homogenized in 96 mL of extraction buffer
(100 mM NaCl, 2 mM CaCl2, 0.25 mM Tris [pH 8.0]) with 0.05%
Tween per milligram tissue weight, using a Precellys tissue homoge-
nizer (Bertin Technologies) and Zirconia beads (Biospec Products).
Homogenates were incubated with 0.92 mg/mL Proteinase K
(Sigma-Aldrich) for 1 hr at 37C and centrifuged for 3 min at
3,000 rpm at 4C. The concentration of QR-110 in the supernatants
was determined using two-step hybridization ELISA. First, QR-110
was captured by a fully phosphorothioated biotin-labeled probe
(complementary to the 30 end of QR-110) onto a streptavidin-coated
MSD plate (Meso Scale Diagnostics). Next, the plate was washed and
incubated with a digoxigenin-labeled detection oligonucleotide probe
(complementary to the 50 end of QR-110). Following washing, the
plate was incubated with sheep anti-Digoxigenin antibody (Roche),
washed and incubated with Sulpho-Tag donkey anti-sheep antibody
(Meso Scale Diagnostics), and analyzed on a Meso Scale Sector S600
(Meso Scale Diagnostics). Calibration curves, generated using four-
parameter logistic (4PL) curve ﬁt regression (weighing factor =
1/Y2), were used to calculate the concentration of QR-110 in the
test samples.
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